超高剂量的甲基巴胺和其他新兴治疗方法用于肌缩性侧面硬化症
Ryuji Kaji1, Yuishin Izumi, Ryosuke Oki
1Department of Neurology, Tokushima University, Tokushima, Japan.
Current opinion in neurology
|July 31, 2024
概括
超高剂量的甲基可巴胺显示出作为一种改变肌缩侧面硬化症 (ALS) 疾病的治疗方法的前景,显著减缓进展并减少 homocysteine. 最佳的临床试验设计对于ALS药物开发至关重要.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肌缩侧面硬化症 (ALS) 病理生理学的理解正在进步,许多候选药物正在开发中.
- 超高剂量的甲基可巴胺是一种关键药物,即将在日本获得批准.
- 现有和新型的ALS治疗策略需要仔细评估.
研究的目的:
- 审查有前途的ALS候选药物,重点是超高剂量的甲基可巴胺.
- 讨论最优的临床试验设计,用于肌缩性侧面硬化症研究.
- 要突出同类半氨酸在ALS病变发生中的作用.
主要方法:
- 关于ALS治疗的最近临床试验数据的审查.
- 对超高剂量甲基巴胺的JETALS第三阶段试验的分析.
- 对之前的研究 (E761试验) 和较新的药物 (AMX0035/Relyvrio) 的检查.
主要成果:
- 在JETALS试验中,超高剂量的甲基可巴胺显著减缓了ALS的进展 (ALSFRSR变化) 并降低了同类半氨酸水平.
- 对E761试验的特设分析表明,在ALS发病一年内开始使用甲基服胺时,甲基服胺对生存有好处.
- AMX0035/Relyvrio 3 期试验产生了负面结果,可能是由于缺乏疾病进展率调整.
结论:
- 超高剂量甲基可巴胺是一种新型疾病修饰性治疗ALS,而不仅仅是补充剂,强调了同类半氨酸的重要性.
- 对ALS进行有效的临床试验需要早期招募患者,并按进展率分层,可能使用试验前观察期.
- 关节性脊髓炎是一种异质性疾病,需要精细的试验设计才能产生有意义的治疗结果数据.
相关概念视频
01:22Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172
01:20Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
114
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
114